tbuckley/cabot-search huggingface dataset:
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
Authors: Youn H. Kim, Martine Bagot, Pier Luigi Zinzani, Madeleine Duvic, Stephen Morris, Ellen Kim, Amy Musiek, Pablo L. Ortiz-Romero, Craig Elmets, Herbert A. Eradat, Nina Magnolo, Julia Scarisbrick, Stéphane Dalle, David C. Fisher, Michi Shinohara, Brian Poligone, Barbara Pro, Pietro Quaglino, Nishitha Reddy, Brigitte Dreno, Larisa J Geskin, Ahmad S Halwani, Amit Khot, Marie Beylot-Barry, Neil Korman, Frederick Lansigan, Steven M. Horwitz, Zanetta S. Lamar, Alison J. Moskowitz, Jillian Wells, Oleg E. Akilov, Dolores Caballero, Richard Cowan, Reinhard Dummer, Mary Jo Lechowicz, Francine M. Foss, Lars Iversen, Tomomitsu Miyagaki, Ryan Wilcox, Pierluigi Porcu, Maarten Vermeer, Sunil Abhyankar, Yukihiko Kato, Theresa Pacheco, Shigetoshi Sano, Basem M. William, Timothy S. Fenske, Noriko Fukuhara, Koji Habe, Toshihisa Hamada, Eiji Kiyohara, Bryone J. Kuss, Adam Lerner, Lawrence Mark, Javier Munoz, Hiroyuki Okamoto, Christiane Querfeld, Jiro Uehara, Hisashi Uhara, Kentaro Yonekura, Auris Huen, Kensei Tobinai, Yoshiki Tokura, Erin Boh, Jan Nicolay, Hidefumi Wada, Mollie Leoni, Takahiro Ito, Fiona Herr, Lubomir Sokol
Journal: Blood (2019)
Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.
Authors: Ken H. Young, Karen Leory, Michael B. Møller, Margarita Sánchez-Beato, Gisele W.B. Colleoni, Fabio R. Kerbauy, Prasad P.K. Koduru, Corinne Haioun, Philippe Gaulard, Miguel A. Piris, Elias Campo, Jan Delabie, Randy D. Gascoyne, Andreas Rosenwald, German Ott, James Huang, Rita M. Braziel, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Kazunori Kanehira, William M. Rehrauer, Jens C. Eickhoff, Brad S. Kahl, James S. Malter, Wing-Chung Chan, Dennis D. Wisenburger, Timothy C. Greiner
Journal: Blood (2006)
Correction
Journal: BMJ (1951)

ANY QUESTIONS?MEDICJOUN New Treatments of Peptic Ulcer Q.-ln the treatment of peptic ulcers is (1) " robaden" or (2) cabbage juice of any value?What are the details of cabbage-juice therapy, if it is useful ?A.-(l) Robaden preparations (variously spelt as robadin and robuden) are, to quote the manufacturers, " protein-free extracts obtained from the tissue of the stomach and small
Awards
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sonographic antepartum diagnosis of conjoined twins. Its impact on obstetric management
Authors: R. M. Gore
Journal: JAMA (1982)

The antepartum diagnosis of conjoined twins is difficult but extremely important for maximization of infant viability and reduction of maternal morbidity. Certain characteristic sonographic and radiological features of anteriorly joined twins allow the diagnosis to be made with some certainty. We describe a case of thoraco-omphalopagus twins in which the prepartum diagnosis was made according to these criteria, and we discuss the impact of early diagnosis on obstetric management. (<i>JAMA</i>1982;247:3351-3353)
HAVANA'S EXCELLENT SANITARY RESULTS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized trial of a web-based intervention to address barriers to clinical trials.
Authors: Neal J. Meropol, Terrance Lynn Albrecht, Yu-Ning Wong, Al Bowen Benson, Joanne S. Buzaglo, Michael Collins, Jennifer Rachel Eads, Brian Egleston, Anne Lederman Flamm, Linda Fleisher, Michael S. Katz, Tyler G. Kinzy, Sharon Manne, Seunghee Margevicius, Dawn M. Miller, Suzanne M. Miller, David Poole, Nancy Roach, Eric A Ross, Mark D. Schluchter
Journal: Journal of Clinical Oncology (2013)

6500 Background: Cancer patients (pts) have knowledge and attitudinal barriers to participation in clinical trials (CT). We developed PRE-ACT (Preparatory Education About Clinical Trials), a tailored, interactive, web-based intervention to address these barriers and improve preparation for consideration of CT as a treatment option. Methods: We conducted a prospective, randomized, multicenter, phase III clinical trial of PRE-ACT vs. control (general text about CT excerpted from NCI materials). All assessments and interventions were conducted online. Cancer pts &gt;18 years old were enrolled before initial oncologist consultation. Pts completed a baseline assessment including CT knowledge (19-item); CT attitudes (28-item); preparation for decision making (10-item); and validated measures of preferences for shared decision making and quality/length of life. PRE-ACT pts received a summary of their preferences and a list of their top CT barriers. Based on ranking of individual barriers, pts were presented with a video library of 30-90 second clips addressing their top barriers (10 maximum). After the educational intervention a follow up survey reassessed CT barriers and preparation. Results: 1255 pts were randomized; median age 59 (range 20-88); 58% female; 12% non-white / 2% Hispanic; 76.4% some college education. 1081 pts completed baseline and post-intervention assessments. The control and PRE-ACT groups both had improved knowledge, reduced attitudinal barriers, and improved preparation (p&lt;.0001 for all comparisons). PRE-ACT was more effective than control in improving knowledge (p=.0006) and attitudes (p&lt;.0001). Furthermore, pts in the PRE-ACT arm were more satisfied with the amount (p=.002) and format (&lt;.0001) of information, and felt more prepared to consider CT (p=.0003). Conclusions: This large-scale randomized trial of a tailored, web-based, video intervention demonstrates that educational information delivered online before the oncologist visit can significantly reduce knowledge barriers and attitudinal barriers and improve preparation for consideration of clinical trials. Both text and PRE-ACT are effective, with greater improvements and satisfaction in the PRE-ACT group. Clinical trial information: NCT00750009.
Two outbreaks of egg-borne salmonellosis and implications for their prevention
Authors: E. A. Ager
Journal: JAMA (1967)

Two large outbreaks of salmonellosis originating in Spokane, Wash, in 1962 and 1963 were traced to commercially baked meringue pies. The presumptive source was bulk egg whites produced locally. Approximately 15, 000 cans of frozen egg products were seized and examined bacteriologically. Of 1,131 core samples of egg whites, 235 (20.8%) were found contaminated with one or more of seven different salmonella serotypes. The heavy contamination of poultry feeds and bulking of large quantities of cracked and dirty eggs without pasteurization are believed to have been responsible for the outbreaks in Spokane as well as several other serious outbreaks documented since 1960.
Treatment of primary and secondary syphilis. Serological response
Authors: N. J. Fiumara
Journal: JAMA (1980)

One hundred thirty-eight patients with primary syphilis and 161 patients with secondary syphilis were treated with penicillin G benzathine, 2.4 million units given intramuscularly weekly for two weeks, for a total of 4.8 million units. All 138 patients with primary syphilis had a rapid resolution of their lesions, and all became seronegative within one year. Similarly, the 161 patients with secondary syphilis were cured clinically, and all achieved seronegativity within 24 months. (<i>JAMA</i>243:2500-2502, 1980)
OVARIOTOMY.
Authors: Donald Maclean
Journal: JAMA (1884)

72Lafayette Ave., Detroit, Mich., November 20, 1884. <h3>To the Editor:</h3><h3>Dear Sir:</h3> —As a kind of a sequel to the letter which I sent you a few days ago, as well as to other articles to which that letter was related, I beg leave to submit the following condensed statement of "<i>facts and figures</i>:" Between January 1 and October 31, 1884, (10 months) I performed exactly twelve ovariotomies. Of these,<i>seven</i>were performed in public amphitheatres, namely:<i>four</i>at Ann Arbor before at least 400 students and medical men, and<i>three</i>at Harper Hospital, in this city, before promiscuous gatherings of students and medical men. Of the four done at Ann Arbor<i>one</i>was a frail old lady of 68. The tumor weighed over forty-five pounds; there were many adhesions; the peritoneal cavity was open for fifty-five minutes; many ligatures were tied, and much sponging was required. She
P01.093 The level of reporting of neurocognitive outcomes in randomized controlled trials of brain tumour patients: a systematic review
Authors: E J J Habets, M J B Taphoorn, M Klein, T Vissers, L Dirven
Journal: Neuro-Oncology (2018)

Neurocognitive impairment is frequently present in brain tumour patients and is therefore considered an important outcome in brain tumour research. To use neurocognitive outcomes (NCO) in clinical decision-making, neurocognitive evidence should be of sufficiently high quality. One important aspect in the generation of high quality evidence is the level of reporting. We aimed to investigate the level of neurocognitive functioning reporting in randomized controlled trials (RCTs) in brain tumour patients. We conducted a systematic literature search in several databases up to August 2017. Of the selected relevant RCTs, the following data were retrieved: basic trial demographics and NCO characteristics, quality of NCO reporting, and risk of bias. We also analyzed studies that should impact clinical decision-making based on their quality of reporting, and assessed the level of the neurocognitive test battery used. We identified 65 RCTs, of which NCO was the primary endpoint in 14 (22%). The included brain tumour types varied, with 20 RCTs studying glioma patients (31%) and 17 studying brain metastatic patients (26%) only. Radiotherapy and chemotherapy were the most studied treatments (both in 31% of studies). In five studies (8%), rehabilitation of neurocognitive impairments was investigated. Important methodological limitations were related to the documentation of statistical approaches for dealing with missing data (not stated in 79% of studies with NCO as primary endpoint and in 73% studies with NCO as secondary endpoint), and to discussing limitations and generalizability issues uniquely related to the NCO components (lacking in 79% of primary and 73% of secondary NCO studies). On the other hand, most studies identified NCO as outcome in the abstract (100% for primary and 86% for secondary NCO). Compared to studies with NCO as secondary endpoint, more studies with NCO as primary endpoint reported a hypothesis (25% versus 79%) and described methods of collecting data (24% versus 57%). Risk of bias was high regarding blinding of personnel and incomplete outcome data, and low regarding blinding of outcome assessment. Overall, lower quality reporting NCO studies did not have more high risk of biases compared to higher quality reporting studies. Twenty RCTs (31%), eight with NCO as primary endpoint and 12 as secondary endpoint, satisfied a sufficient number of criteria to be classified as ‘high-quality’ NCO evidence. Most of these studies did contribute to clinical decision-making, while only 50% included an adequate neurocognitive test battery. Investigators involved in brain tumour research should give attention to methodological challenges related to NCO reporting as identified in this review, as ‘high-quality’ reporting of NCO evidence can be of value in clinical decision-making.
Contents
Authors: Jessica Shantha, Ian Crozier, Brent Hayek, Beau Bruce, Catherine Gargu, Jerry Brown, John Fankhauser, Steven Yeh, Sandrine Zweifel, Daniela Mihic-Probst, Christine Curcio, Daniel Barthelmes, Andrea Thielken, Peter Keller, Barbara Hasse, Christian Böni, Tyler Calway, Daniel Rubin, Heather Moss, Charlotte Joslin, Katharina Beckmann, Steven Roth, Alison Skalet, Yan Li, Chen Lu, Yali Jia, Byungkun Lee, Lennart Husvogt, Andreas Maier, James Fujimoto, Charles Thomas, David Huang, Karen Schaal, Andrew Legarreta, William Feuer, Giovanni Gregori, Qianqian Cheng, John Legarreta, Mary Durbin, Paul Stetson, Sophie Kubach, Philip Rosenfeld, Nizar Abdelfattah, Mayss Al-Sheikh, Sean Pitetta, Ahmed Mousa, Srinivas Sadda, Charles Wykoff, Glenn Jaffe, Thomas Ciulla, Antonio Ciardella, Francois Devin, Pravin Dugel, Chiara Eandi, Harvey Masonson, Jordi Monés, Joel Pearlman, Maddalena Quaranta-El Maftouhi, Federico Ricci, Keith Westby, Samir Patel, Abhishek Dave, Ramesh Venkatesh, Umang Mathur
Journal: Ophthalmology (2017)
Sorbinil and limited joint mobility in diabetics
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The finding of Eaton et al,<sup>1</sup>that administration of the aldose-reductase inhibitor, sorbinil, markedly improves joint mobility in the hands of diabetic patients, is of considerable interest. However, I take issue with their suggested explanation, namely, that it is due to reduction of excessive hydration of tendon collagen, produced by decreasing the local concentration of sorbitol. Recently, we<sup>2</sup>and others<sup>3</sup>have also reported changes in extracellular matrix with marked thickening and other morphological alterations of vascular basement membranes in galactosemic rats. These changes appeared to be identical with the abnormalities seen in diabetic patients, and they could also be prevented by sorbinil. We hesitated to explain these findings using the osmotic hypothesis that has been advanced to explain diabetic and galactosemic cataractogenesis,<sup>4</sup>and that, in only slightly varied form, Eaton et al appear to be proposing to explain their results. The reason is
Adventures in Autopharmacology: A Biographic View with Digressions into Other Matters
Authors: M. Rand
Journal: The Annual Review of Pharmacology and Toxicology (1993)

Heme oxygenases (HO) catabolize free heme, that is, iron (Fe) protoporphyrin (IX), into equimolar amounts of Fe2+, carbon monoxide (CO), and biliverdin. The stress-responsive HO-1 isoenzyme affords protection against programmed cell death. The mechanism ...Read More
Single-day loading dose of oral amiodarone does not prevent atrial fibrillation after coronary artery bypass surgery Dejan Maras, Srdjan Boskovic, Slobodan Kovacevic, Petar Otasevic, Zoran Popovic, Rade Babic, Ljilja Vuk, Tomislav Jovanovic, Milovan Bojic, Aleksandar Neskovic. Dedinje Cardiovascular Institute, Belgrade, Yugoslavia
Journal: Journal of the American College of Cardiology (2001)
Myocardial infarction and cigarette smoking in women younger than 50 years of age
Authors: L. Rosenberg
Journal: JAMA (1985)

The modifying influence of individual risk factors on the relation between myocardial infarction (MI) and cigarette smoking was evaluated in a case-control study of women younger than 50 years of age. Data from 555 women who survived first MIs were compared with those of 1,864 hospital controls of similar ages. The risk of MI increased with the number of cigarettes smoked, both in the presence and absence of factors that predispose to an infarction. In particular, the association was apparent at all ages, at all levels of total serum cholesterol and high-density lipoprotein cholesterol, and in the presence and absence of oral contraceptive use, hypertension, diabetes mellitus, blood group A, tendency to type A behavior, and family history of MI. The relative increase in risk was generally greater the lower the underlying predisposition to MI. There was clear evidence, however, that recent oral contraceptive use substantially augmented the increased risk for smokers, and hypercholesterolemia may have had the same effect. (<i>JAMA</i>1985;253:2965-2969)
Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.
Authors: Bernardo Leon Rapoport, Lee Steven Schwartzberg, Sujata Arora, Daniel Powers, Karin Jordan, Rudolph M. Navari
Journal: Journal of Clinical Oncology (2016)

10122 Background: Rolapitant, a long-acting neurokinin-1 receptor antagonist, protected against CINV in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). Methods: In 3 double-blind phase 3 studies, patients were randomized to receive oral rolapitant 180 mg or placebo before administration of HEC or MEC. All patients received a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone. In a post hoc analysis of 3 pooled studies (2 HEC and 1 MEC), we assessed the efficacy and safety of rolapitant in patients with gynecologic (ovarian, uterine, or cervical) cancer. Endpoints included complete response (CR; no emesis and no use of rescue medication), no emesis, no nausea (maximum visual analogue scale [VAS] < 5 mm), and complete protection (CP; no emesis, no use of rescue medication, and no significant nausea [maximum VAS < 25 mm]) in the overall (0–120 h), acute ( ≤ 24 h), and delayed ( > 24–120 h) phases. Results: Of 203 patients with gynecologic cancer, 55% received cisplatin-based HEC and 45% received MEC (98% of whom received carboplatin-based therapy). In the overall and delayed phases, improved rates of CR, no emesis, no nausea, and CP were observed with rolapitant compared with control (Table). The overall incidence of treatment-emergent adverse events was similar in the rolapitant and control groups (46% vs 54%). Conclusions: Rolapitant protected against overall and delayed CINV in patients with gynecologic cancer receiving HEC or MEC. Clinical trial information: NCT01500226, NCT01499849, NCT01500213.Endpoint, % Pooled HEC/MEC Rolapitant (n = 107) Control (n = 96) Odds Ratio (95% Confidence Interval) Overall phase (0–120 h) CR 79 64 2.1 (1.1–3.9) No emesis 83 69 2.2 (1.2–4.4) No nausea 60 40 2.3 (1.3–4.0) CP 74 56 2.2 (1.2–4.0) Acute phase ( ≤ 24 h) CR 92 82 2.3 (1.0–5.5) No emesis 92 84 2.0 (0.8–4.8) No nausea 76 68 1.5 (0.8–2.7) CP 85 78 1.6 (0.8–3.3) Delayed phase ( > 24–120 h) CR 79 65 2.1 (1.1–4.0) No emesis 84 71 2.2 (1.1–4.3) No nausea 62 43 2.2 (1.2–3.8) CP 75 57 2.2 (1.2–4.0)
Survival After Reconstructive Surgery for Hypoplastic Left Heart Syndrome
Authors: William T. Mahle, Thomas L. Spray, Gil Wernovsky, J. William Gaynor, Bernard J. Clark
Journal: Circulation (2000)

Background —There are limited data regarding the long-term survival of patients who have undergone reconstructive surgery for hypoplastic left heart syndrome (HLHS). We reviewed the 15-year experience at our institution to examine survival in the context of continued improvements in early operative results. Methods and Results —Between 1984 and 1999, 840 patients underwent stage I surgery for HLHS. From review of medical records and direct patient contact, survival status was determined. The 1-, 2-, 5-, 10-, and 15-year survival for the entire cohort was 51%, 43%, 40%, 39%, and 39%, respectively. Late death occurred in 14 of the 291 patients discharged to home after the Fontan procedure, although only 1 patient has died beyond 5 years of age. Heart transplantation after stage I reconstruction was performed in 5 patients. Later era of stage I surgery was associated with significantly improved survival ( P &lt;0.001). Three-year survival for patients undergoing stage I reconstruction from 1995 to 1998 was 66% versus 28% for those patients undergoing surgery from 1984 to 1988. Age &gt;14 days at stage I and weight &lt;2.5 kg at stage I were also associated with higher mortality ( P =0.004 and P =0.01, respectively). Other variables, including anatomic subtype, heterotaxia, and age at subsequent staging procedures, were not associated with survival. Conclusions —Over the 15-year course of this study, early- and intermediate-term survival for patients with HLHS undergoing staged palliation increased significantly. Late death and the need for cardiac transplantation were uncommon.
L'angine de poitrine et l'angine abdominale.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal